263 related articles for article (PubMed ID: 12036830)
1. Response of Gaucher bone disease to enzyme replacement therapy.
Poll LW; Maas M; Terk MR; Roca-Espiau M; Bembi B; Ciana G; Weinreb NJ
Br J Radiol; 2002; 75 Suppl 1():A25-36. PubMed ID: 12036830
[TBL] [Abstract][Full Text] [Related]
2. Bone complications in children with Gaucher disease.
Bembi B; Ciana G; Mengel E; Terk MR; Martini C; Wenstrup RJ
Br J Radiol; 2002; 75 Suppl 1():A37-44. PubMed ID: 12036831
[TBL] [Abstract][Full Text] [Related]
3. [Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement].
Poll LW; vom Dahl S; Koch JA; Börner D; Willers R; Cohnen M; Jung G; Scherer A; Niederau C; Häussinger D; Mödder U
Rofo; 2001 Oct; 173(10):931-7. PubMed ID: 11588682
[TBL] [Abstract][Full Text] [Related]
4. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
5. Imaging and quantifying skeletal involvement in Gaucher disease.
Maas M; Poll LW; Terk MR
Br J Radiol; 2002; 75 Suppl 1():A13-24. PubMed ID: 12036829
[TBL] [Abstract][Full Text] [Related]
6. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
7. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
[TBL] [Abstract][Full Text] [Related]
8. Reconversion of bone marrow in Gaucher disease treated with enzyme therapy documented by MR.
Allison JW; James CA; Arnold GL; Stine KC; Becton DL; Bell JM
Pediatr Radiol; 1998 Apr; 28(4):237-40. PubMed ID: 9545478
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
[TBL] [Abstract][Full Text] [Related]
11. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
12. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease.
Hollak C; Maas M; Akkerman E; den Heeten A; Aerts H
Blood Cells Mol Dis; 2001; 27(6):1005-12. PubMed ID: 11831867
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase.
Rosenthal DI; Doppelt SH; Mankin HJ; Dambrosia JM; Xavier RJ; McKusick KA; Rosen BR; Baker J; Niklason LT; Hill SC
Pediatrics; 1995 Oct; 96(4 Pt 1):629-37. PubMed ID: 7567322
[TBL] [Abstract][Full Text] [Related]
14. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Javier RM; Hachulla E
Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
[TBL] [Abstract][Full Text] [Related]
15. Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement.
Hermann G; Pastores GM; Abdelwahab IF; Lorberboym AM
Skeletal Radiol; 1997 Dec; 26(12):687-96. PubMed ID: 9453101
[TBL] [Abstract][Full Text] [Related]
16. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.
de Fost M; van Noesel CJ; Aerts JM; Maas M; Pöll RG; Hollak CE
Haematologica; 2008 Jul; 93(7):1119-20. PubMed ID: 18519519
[No Abstract] [Full Text] [Related]
17. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - a histological study.
Rudzki Z; Okoń K; Machaczka M; Rucińska M; Papla B; Skotnicki AB
Eur J Haematol; 2003 May; 70(5):273-81. PubMed ID: 12694162
[TBL] [Abstract][Full Text] [Related]
18. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
Grigorescu Sido P; Drugan C; Cret V; Al-Kzouz C; Denes C; Coldea C; Zimmermann A
J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
[TBL] [Abstract][Full Text] [Related]
19. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Hachulla E; Javier RM
Rev Med Interne; 2007 Oct; 28 Suppl 2():S180-2. PubMed ID: 18228685
[No Abstract] [Full Text] [Related]
20. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
